Skip to main content

Table 4 Univariate analysis of associations between clinical characteristics and SF-36 scores of mRCC patients

From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

Variable

PF score

RP score

BP score

GH score

VT score

SF score

RE score

MH score

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Sex (man vs. woman)

1.690 (0.832–3.434)

0.147

1.384 (0.698–2.744)

0.353

0.750 (0.354–1.591)

0.453

0.879 (0.425–1.814)

0.987

0.793 (0.400–1.572)

0.507

0.976 (0.493–1.932)

0.944

1.709 (0.823–3.552)

0.151

0.857 (0.433–1.699)

0.659

Age (<65 vs. ≥65 years)

0.838 (0.431–1.631)

0.604

0.962 (0.493–1.879)

0.910

0.764 (0.364–1.607)

0.479

1.020 (0.503–2.067)

0.438

1.830 (0.926–3.618)

0.082

0.982 (0.505–1.910)

0.957

1.151 (0.585–2.266)

0.684

1.412 (0.724–2.751)

0.311

MSKCC grade (favorable vs. others)

1.432 (0.609–3.364)

0.410

1.646 (0.707–3.833)

0.248

0.850 (0.335–2.155)

0.732

1.717 (1.132–4.028)

0.034

0.881 (0.381–2.040)

0.768

1.646 (0.701–3.868)

0.253

1.475 (0.576–3.284)

0.474

1.062 (0.458–2.459)

0.899

IMDC risk (good vs. others)

0.442 (0.465–5.794)

0.442

0.436 (0.112–1.695)

0.231

0.478 (0.100–2.283)

0.355

1.171 (0.330–4.153)

0.807

0.536 (0.152–1.892)

0.322

0.851 (0.251–2.887)

0.796

1.321 (0.374–4.667)

0.666

1.395 (0.411–4.733)

0.593

AE grade (1–2 vs. 3–4)

0.802 (0.312–2.074)

0.804

3.845 (1.327–11.139)

0.013

4.513 (1.689–12.127)

0.003

1.544 (0.589–4.047)

0.377

0.860 (0.334–2.219)

0.756

1.876 (0.706–4.985)

0.207

2.234 (0.772–6.469)

0.138

2.715 (0.987–7.466)

0.053

Treatment (sorafenib vs. sunitinib)

1.199 (0.662–2.173)

0.550

1.096 (0.607–1.977)

0.761

1.340 (0.718–2.504)

0.358

0.617 (0.327–1.164)

0.136

0.733 (0.406–1.325)

0.304

1.074 (0.596–1.938)

0.811

1.377 (0.749–2.531)

0.303

1.243 (0.689–2.243)

0.470

  1. PF physical functioning, RP role-physical, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role-emotional, MH mental health, IMDC International Metastatic Renal Cell Carcinoma Database Consortium
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us